**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 58974

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Dried blood spot sampling as an alternative for the improvement of hepatitis B and C diagnosis in key populations**

Flores GL *et al*. DBS for HBV and HCV diagnosis

Geane Lopes Flores, Jakeline Ribeiro Barbosa, Helena Medina Cruz, Juliana Custódio Miguel, Denise Vigo Potsch, José Henrique Pilotto, Danielle Malta Lima, Jeová Keny Baima Colares, Carlos Eduardo Brandão-Mello, Marcia Maria Amendola Pires, Jurema Corrêa da Mota, Francisco I Bastos, Lia Laura Lewis-Ximenez, Livia Melo Villar

**Geane Lopes Flores, Helena Medina Cruz, Juliana Custódio Miguel, Lia Laura Lewis-Ximenez, Livia Melo Villar,** Viral Hepatitis Laboratory, FIOCRUZ, Rio de Janeiro 21040360, Brazil

**Jakeline Ribeiro Barbosa, Jeová Keny Baima Colares,** Postgraduate Program in Pathology, Federal University of Ceará, Fortaleza 60020181, Ceara, Brazil

**Denise Vigo Potsch,** Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro, Rio de Janeiro 21040360, Brazil

**José Henrique Pilotto,** Nova Iguaçu General Hospital, Nova Iguaçu 26041061, Brazil

**José Henrique Pilotto,** Molecular Immunology Laboratory, Oswaldo Cruz Institute, Rio de Janeiro 21040360, Brazil

**Danielle Malta Lima,** Postgraduate Program in Medical Sciences, University of Fortaleza, Fortaleza 60811905, Ceará, Brazil

**Carlos Eduardo Brandão-Mello, Marcia Maria Amendola Pires,** Escola de Medicina e Cirurgia, Gaffrée & Guinle University Hospital, Federal University of Rio de Janeiro State, Rio de Janeiro 20270901, Brazil

**Jurema Corrêa da Mota, Francisco I Bastos,** Institute of Communication and Information on Science and Technology in Health, FIOCRUZ, Rio de Janeiro 21040360, Brazil

**Author contributions:** Villar LM conceived the study; Villar LM and Flores GL designed the research and the study protocol; Potsch DV, Pilotto JH, Lima DM, Baima Colares JK, Brandão-Mello CE, Pires MMA and Lewis-Ximenez LL carried out the participants’ selection and recruitment; Cruz HM, Barbosa JR, Miguel JC and Flores GL performed laboratory assays; da Mota JC and Bastos FI performed the statistical analysis; Flores GL, Villar LM, Mota JC and Bastos FI performed the analysis and interpretation of the data; Flores GL and Villar LM drafted the manuscript; Flores GL, Mota JC, Bastos FI and Villar LM critically revised the manuscript for intellectual content; All authors read and approved the final manuscript.

**Supported by** National Council for Scientific and Technological Development (CNPq); and Foundation for Research Support of the State of Rio de Janeiro (FAPERJ).

**Corresponding author: Livia Melo Villar, PhD, Research Scientist,** Viral Hepatitis Laboratory, FIOCRUZ, Avenida Brasil, 4365, Rio de Janeiro 21040360, Brazil. liviafiocruz@gmail.com

**Received:** August 17, 2020

**Revised:** November 24, 2020

**Accepted:** December 13, 2020

**Published online:**

**Abstract**

BACKGROUND

To achieve the elimination of hepatitis B and C, there is an urgent need to develop alternative strategies to increase the access of diagnosis, particularly among key populations such as people living with human immunodeficiency virus (HIV), individuals with coagulopathies and chronic kidney disease (CKD) patients.

AIM

To evaluate the use of dried blood spot (DBS) in the detection of hepatitis B virus (HBV) and hepatitis C virus (HCV) markers.

METHODS

A total of 430 individuals comprised of people living with HIV, coagulopathies and CKD provided paired serum and DBS samples. HBsAg, anti-HBc and anti-HCV were tested in those samples using a commercial electrochemiluminescence. Demographic and selected behavioral variables were evaluated to assess possible association with HBV and HCV positivity.

RESULTS

Using DBS, HBsAg prevalence varied from 3.9% to 22.1%, anti-HBc rates varied from 25.5% to 45.6% and anti-HCV positivity ranged from 15.9% to 41.2% in key populations. Specificities of HBV and HCV tests using DBS varied from 88.9% to 100%. The HBsAg assay demonstrated the best performance in CKD and coagulopathy individuals and the anti-HCV test had a sensitivity and specificity of 100% in people living with HIV. Accuracy of HBV and HCV detection in DBS varied from 90.2% to 100%. In the CKD group, HBsAg positivity was associated with infrequent use of condoms, and anti-HBc positivity was associated with sharing nail cutters/razors/toothbrushes. Anti-HCV reactivity was positively associated with a history of transplantation and length of time using hemodialysis in both specimens. In people living with HIV, only the male gender was associated with anti-HBc positivity in serum and DBS.

CONCLUSION

DBS with electrochemiluminescence are useful tools for the diagnosis and prevalence studies of hepatitis B and C among key populations and may increase the opportunity to foster prevention and treatment.

**Key Words:** Dried blood spot; Electrochemiluminescence; Hepatitis B; Hepatitis C; Key populations; Diagnosis

Flores GL, Barbosa JR, Cruz HM, Miguel JC, Potsch DV, Pilotto JH, Lima DM, Baima Colares JK, Brandão-Mello CE, Pires MMA, da Mota JC, Bastos FI, Lewis-Ximenez LL, Villar LM. Dried blood spot sampling as an alternative for the improvement of hepatitis B and C diagnosis in key populations. *World J Hepatol* 2020; In press

**Core Tip:** Dried blood spot (DBS) samples may be an alternative to serum to increase access and timeliness in the diagnosis of hepatitis B and C in key populations such as people living with human immunodeficiency virus, coagulopathies and chronic kidney disease. We found high accuracy for hepatitis B virus and hepatitis C virus detection using DBS. It was possible to observe similar hepatitis prevalence, demographic and clinical data related to hepatitis positivity in DBS and serum. DBS along with electrochemiluminescence could be used for diagnosis and prevalence studies of hepatitis B virus and hepatitis C virus among hard-to-reach populations.

**INTRODUCTION**

Viral hepatitis is an important public health challenge with an estimated 257 million people living with chronic hepatitis B virus (HBV) and 71 million people living with chronic hepatitis C virus (HCV) worldwide[1,2]. HBV and HCV infection have a heterogeneous distribution in Latin America, where 7-12 million people have been infected with HBV and less than 2% are infected with HCV[3].

Some groups may be exposed more frequently to HBV and HCV infection mainly due to repeated exposure to contaminated blood that may occur during transfusions, hospitalizations, surgeries as well as other invasive procedures (including the management of chronic kidney disease (CKD) *via* hemodialysis) and last but not least coagulopathy individuals. In these groups, HBsAg prevalence varies from 3.9% to 7.0% and anti-HCV prevalence from 12.6% to 47.0%[4-8]. Another group at-risk for acquiring HBV and HCV is composed of people living with human immunodeficiency virus (HIV), as those viruses share common modes of transmission, such as sexual and parenteral transmission. Among people living with HIV, HBV prevalence varies from 2.8% to 10.3%, while HCV prevalence varies from 4.6% to 6.4%[3,7,9,10].

Diagnosis of infections with these viruses can be difficult in these at-risk groups, such as CKD individuals undergoing hemodialysis, coagulopathy individuals and people living with HIV, due to the difficulty of blood sample collection by venipuncture, their remote location and lack of health care.

In these real-life situations, biosecurity is an ever-present problem. In addition to difficulties affecting proper storage and transport of materials and samples, trained personnel are usually absent or scarce. Dried blood spot (DBS) samples could be a key alternative to serum obtained by venipuncture, which would increase access to diagnosis. These samples are easily collected using finger puncture and can be transported and stored at room temperature. Some studies have demonstrated the detection of HBV and HCV markers using DBS along with enzyme-linked immunosorbent assay in several groups, including monoinfected hepatitis patients and those coinfected with HIV[11-13].

Most studies aiming to detect hepatitis markers in DBS have employed enzyme immunoassays, but recently several laboratories have replaced manual or semimanual enzyme-linked immunosorbent assay with electrochemiluminescence (ECLIA). This technique is highly accurate, presents a low detection limit and delivers results quickly[14]. ECLIA has been used for detecting HBsAg and anti-HCV in DBS samples in monoinfected individuals with high sensitivity and specificity[15]. However, there is no information regarding the performance of ECLIA for the detection of HBV and HCV markers in DBS samples in key populations, such as individuals with coagulopathies, CKD patients and people living with HIV.

The main objective of this study was to investigate the putative influence of HIV infection as well as pathophysiological alterations in individuals with coagulopathies (hemophilia and von Willebrand disease) or CKD, vis-à-vis the performance of optimized ECLIA for the detection of HBsAg, anti-HBc and anti-HCV markers in DBS samples. This study also aimed to provide new data on the prevalence of these markers using DBS coupled with ECLIA.

**MATERIALS AND METHODS**

***Study design and population***

A cross-sectional study was conducted in different macro-regions of the country from June 2014 to March 2017. Basic sociodemographic data were collected using a standard questionnaire. While analyzing at-risk populations in Brazil presents inherent limitations in the sample-frames available, this study aimed to create a panel that was as broad as possible to maximize the use of individuals and samples obtained under the protocol.

Convenience samples include those as follows: coagulopathy individuals, CKD patients and people living with HIV. Potential participants were recruited from hemodialysis clinics. Among them, coagulopathy individuals under follow-up in referral clinics as well as patients from HIV/AIDS services located in the northeastern and southeastern regions of Brazil were recruited.

These geographical domains correspond to an involuntary but insurmountable limitation. Although there are some data on the southernmost regions of Brazil from other research groups, data on the far north and central west locations represent a challenge in terms of budgetary constraints and logistics. To send research teams to such locations and to transport biological samples over such huge distances requires a sustained effort and costs comparable to travel across the whole territory of western Europe. Furthermore in Brazil, personnel (both technicians and ancillary personnel) and sample transportation remain a challenge due to a fractured and sometimes nonexistent aerial and terrestrial network.

Inclusion criteria for the selection of participants were as follows: individuals of both sexes, aged 18 years or older, attending the healthcare centers involved in this study for their different medical conditions.

Three groups were included in this study: (1) Individuals with coagulopathies (hemophilia and von Willebrand disease) recruited from the coagulopathy outpatient clinic of the public Hematology and Hemotherapy Center of Ceará (Hemoce), located in Fortaleza city; (2) CKD patients on hemodialysis recruited from three private nephrology clinics that receive individuals from the public and private healthcare systems located in the states of Ceará and Rio de Janeiro; and (3) People living with HIV referred to the viral hepatitis ambulatory clinic (FIOCRUZ, RJ) from the gastroenterology outpatient clinic of the Gaffrée and Guinle Hospital (UNIRIO, RJ) infectious disease unit at Nova Iguaçu Hospital and the infectious disease outpatient clinic at the Clementino Fraga Filho Hospital (UFRJ).

Demographic characteristics and risk factors such as behavior, age, gender, marital status and education were defined using categories in the Brazilian Census and major national household surveys (*e.g.*, PNAD). All patients enrolled read and signed the informed consent form. The FIOCRUZ Ethics Committee approved this study (CAAE No. 34049514.7.3006.5258 e 34049514.7.3009.5051).

***Laboratory tests***

Paired serum and DBS samples were obtained by venipuncture. Whole blood (6 mL) was collected from each patient and 75 μL of this was applied to a 12 mm, preprinted circular disc on Whatman 903 protein protective card (Whatman, GE Healthcare, NJ, United States). To elute DBS samples, the 12 mm disc of filter paper was cut and transferred to a microtube containing 500 μL of 0.5% PBS/BSA for 18 h to 24 h[15]. The analysis of the serum samples was the gold standard for the detection of HBsAg, anti-HBc and anti-HCV. Serological markers were detected using a commercial ECLIA technique (Cobas E411, Roche, United States).

***ECLIA in DBS samples***

The ECLIA technique was used for the evaluation of HBsAg, anti-HBc and anti-HCV in DBS samples (Elecsys anti-HCV II, Elecsys HBsAg II and Elecsys anti-HBc II - Roche Diagnostics) following the manufacturer’s instructions. In the anti-HCV and HBsAg assay, samples with sample/cutoff values < 1.0 were considered nonreactive, whereas for the anti-HBc assay, non-reactive samples should have an sample/cutoff value of > 1.0.

***Statistical analysis***

Absolute and estimated infection frequencies were calculated as well as mean and standard deviation of the patients’ sociodemographic and clinical characteristics. For the association study, populations and markers were analyzed using the Chi-square test for homogeneity with a *P* value of 0.05. Variables with a proportion of missing values greater than 10.0% for each diagnostic test were excluded from the analysis. Unadjusted odds ratios (ORs) and respective 95% confidence intervals (95%CIs) were calculated for sociodemographic, behavioral and clinical variables as well as for each one of the diagnostic tests/seromarkers.

Associations were further analyzed using multiple logistic regression. Nonreactive samples were taken as the reference categories to which all other categories were cross-compared, yielding adjusted ORs and respective CIs. Only variables with statistical association at the level of 20% were entered into the multivariate models using a forward stepwise procedure. Maximum likelihood and the Wald test were used to assess the parsimony and fitness of intermediate models contemplating the exclusion or inclusion of different variables. Intermediate models were evaluated using the Hosmer-Lemeshow goodness-of-fit test using a 95%CI.

Taking ECLIA as the gold standard method for the sake of our analysis, sensitivity, specificity and positive and negative predictive values as well as accuracy were calculated for each biological outcome.

**RESULTS**

***CKD patients***

Among CKD patients (*n* = 284), HBsAg, anti-HBc and anti-HCV were detected in serum in 4.6%, 39.9% and 16.3% of individuals, respectively and were detected by DBS in 4.9%, 33.6% and 15.9% of individuals, respectively. Table 1 shows the sociodemographic and clinical characteristics of this population.

Most CKD patients were male (62.7%), over 30-years-old (93.0%), black (72.4%) and had up to 8 years of education (51.1%). The most risk behaviors were: shared nail cutters/razors/toothbrushes (66.9%), previous transfusion of plasma or blood (63.3%), inconsistent use of condoms (74.4%) and the use of hemodialysis up to 3 times a week (89.5%).

HBV and HCV serological markers in DBS and serum were evaluated according to demographic and clinical data. Only statistically significant data are presented in Table 2. Infrequent use of condoms was associated with HBsAg positivity in serum and DBS (OR = 5.6 for serum and 4.4 for DBS). Sharing nail cutters/razors/toothbrushes was associated with anti-HBc positivity in serum and DBS (OR = 2.7 for serum and 2.6 for DBS). On the other hand, acupuncture and hemodialysis exposure was associated with anti-HBc detection in serum and a history of transplantation in DBS. Anti-HCV positivity was associated with a history of transplantation (OR = 2.8 for serum and DBS) and hemodialysis exposure (OR = 1.01 for both specimens).

***People living with HIV***

Among people living with HIV (*n* = 95), the mean age was 44.1 ± 11.4 years. Most individuals were male (61.1%), unmarried (64.8%), over 30-years-old (90.4%) and sharing nail cutters/razors/toothbrushes (74.5%) (Table 1). The prevalence of HBsAg+ in serum/DBS was 21.0%/22.1%, of anti-HBc+ was 40.0%/45.6% and anti-of HCV+ was 25.5%/25.5%.

Table 3 shows the factors associated with the detection of HBV and HCV serological markers using DBS and serum in this group. Male gender (OR = 4.9) and blood transfusion (OR = 4.6) were associated with HBsAg reactivity in serum, while male gender was associated with anti-HBc positivity in serum (OR = 3.2) and DBS (OR = 2.9). No variable was associated with anti-HCV in this group.

***Individuals with coagulopathy***

Among coagulopathy patients (*n* = 51), the mean age was 31.3 ± 9.4 years and the main characteristics were: male gender (98.0%), unmarried (66.7%), black (70.8%), had undergone blood or plasma transfusion (70.0%) and had severe hemophilia (71.7%) (Table 1).

The prevalence for each seromarker in serum was 3.9% for HBsAg, 31.4% for anti-HBc and 47.1% for anti-HCV. The prevalence for each seromarker from DBS was 3.9% for HBsAg, 25.5% for anti-HBc and 41.2% for anti-HCV. It was not possible to make a statistical analysis of this group due to the small size of the sample population.

***Performance of ECLIA for HBV and HCV detection using DBS samples in high-risk groups***

Among coagulopathy patients, HBsAg assay demonstrated the best performance (100% sensitivity and specificity) followed by anti-HBc (81.3% sensitivity and 100% specificity) and anti-HCV (83.3% sensitivity and 96.3% specificity). Among CKD patients, the best performance was observed for HBsAg (100% sensitivity and 99.6% specificity) followed by anti-HCV (93.5% sensitivity and 99.2% specificity) and anti-HBc (79.6% sensitivity and 97.1% specificity). Among people living with HIV, the best performance was observed for anti-HCV (100% sensitivity and specificity) followed by anti-HBc (97.2% sensitivity and 88.9% specificity) and HBsAg (85.0% sensitivity and 94.7% specificity).

Accuracy varied from 90.2% to 100% and incorrect classification was below 10% in all markers. Estimated prevalence varied between serum and DBS in coagulopathy patients, and CKD individuals showed low values of prevalence using DBS for anti-HBc and anti-HCV. In people living with HIV, estimated prevalence for HBsAg and anti-HBc were higher using DBS (Table 4).

**DISCUSSION**

To date, there are several studies reporting the importance of diagnosing hepatitis B and C in DBS samples[16-18]. However, the majority have focused only on HBsAg[13,16] and anti-HCV[11] along with manual assays. In the present study, an automated assay was evaluated for the detection of HBsAg, anti-HBc and anti-HCV in DBS samples from key populations demonstrating high sensitivities and specificities comparable to those observed in the general population[15]. These findings reinforce the importance of using DBS samples to reach these key populations in the diagnosis of viral hepatitis, which can be further facilitated using ECLIA.

Among CKD patients, HBsAg positivity in DBS or serum was associated with infrequent condom use, which was also found among young men enlisted in the Brazilian Army, demonstrating the importance of health campaigns with a focus on condom use[19]. Anti-HBc positivity in serum and DBS was associated with shared nail cutters/razor/toothbrush and highlights the discussion of the role of manicurists in the transmission of HBV. Villar *et al*[20] found a prevalence of 5.9% of anti-HBc in beauty professionals in southeast Brazil.

Anti-HCV positivity in serum and DBS was associated with a previous history of transplantation in CKD patients. A study that assessed the risk of transplant recipient infections showed that this will depend on the prevalence and incidence of HCV in a given population of donors and other risk exposures such as injecting drug use, men who have sex with men, piercings and tattoos. These, among other risk factors, are already associated with transmission for the general population[21].

Among people living with HIV, HBsAg positivity was associated with male gender and blood and plasma transfusion using serum results, and anti-HBc positivity was associated with male gender using the results of both fluids. In Brazil, most HBV infected individuals were male (54.5%)[22], probably due to higher exposure to risk factors, such as promiscuity and drug use[23,24]. Although blood is screened for HBsAg and anti-HBc in blood banks in Brazil, molecular assays were only included in 2015. While rare, occult hepatitis B infection, mutations that escape vaccination and infected individuals occupying a certain immunological window could be potential donors of contaminated blood samples allowing HBV transmission[25,26].

DBS testing for HBsAg, anti-HBc and anti-HCV using ECLIA demonstrated high sensitivity and specificity in all groups. HBsAg testing demonstrated the best performance in coagulopathy individuals and CKD patients. Anti-HCV testing demonstrated higher efficiency in CKD individuals and people living with HIV and anti-HBc detection was more accurate in people living with HIV. The differences observed could be the result of different prevalences and risk behavior, such as multiple exposure to blood products that could interfere in the efficiency of the assay.

HBsAg and anti-HCV prevalence estimated by serum and DBS were similar in demonstrating that ECLIA along with DBS could be a potential tool for diagnosis of infected individuals in key populations. In contrast, anti-HBc prevalence varied by more than 5% between serum and DBS in all groups evaluated. In the present study, anti-HBc sensitivity varies from 79.6% to 97.2%, which is similar to findings in other studies that reported sensitivities from 76.9% to 97.6% using ECLIA or enzyme-linked immunosorbent assay for anti-HBc in the general population and people living with HIV[12,13,16]. Although there are differences found in anti-HBc prevalence in serum and DBS, there is an overlapping CI value for those specimens showing that DBS could be used for prevalence studies in key populations.

**CONCLUSION**

This study demonstrated the utility of HBsAg, anti-HBc and anti-HCV detection in DBS using ECLIA in high-risk populations. The use of DBS samples is much less invasive, easier than venipuncture and could increase the access of diagnosis in people with limited social access as well as in people where it is difficult to draw blood. Automated assays such as ECLIA using DBS increases diagnostic speed, generating the diagnosis of many samples at once, which can be important during potential outbreaks in hemotherapy clinics for example. However, the anti-HBc marker should be used with due care, especially in the population of coagulopathy individuals and CKD patients, which due to multiple exposures may not show agreement with gold standard samples and therefore requires further study.

**ARTICLE HIGHLIGHTS**

***Research background***

Diagnosis of hepatitis B virus and hepatitis C virus (HCV) can be difficult in chronic kidney disease (CKD) individuals undergoing hemodialysis, coagulopathy individuals and people living with human immunodeficiency virus (HIV) due to the difficulty of blood sample collection by venipuncture, remote location and lack of health care.

***Research motivation***

There is no information regarding the performance of electrochemiluminescence (ECLIA) for the detection of hepatitis B virus and HCV markers in dried blood spot (DBS) samples in key populations, such as individuals with coagulopathies, CKD patients and people living with HIV.

***Research objectives***

To investigate the putative influence of HIV infection as well as pathophysiological alterations in individuals with coagulopathies (hemophilia and von Willebrand disease) or CKD in the performance of optimized ECLIA for the detection of HBsAg, anti-HBc and anti-HCV markers in DBS samples.

***Research methods***

The ECLIA technique was used for the evaluation of HBsAg, anti-HBc, and anti-HCV tests in DBS samples of CKD individuals undergoing hemodialysis, coagulopathy individuals and people living with HIV.

***Research results***

HBsAg detection presented sensitivities of 100% among coagulopathy and CKD patients and low sensitivity (85.0%) in people living with HIV. Anti-HBc detection had the best performance in people living with HIV followed by coagulopathy and CKD patients. Anti-HCV detection showed sensitivities above 83.0% in all groups. Specificities of these assays varied from 88.9% to 100%. Estimated prevalence was similar among serum and DBS except for the anti-HBc marker.

***Research conclusions***

This study demonstrated the utility of HBsAg, anti-HBc and anti-HCV detection in DBS using ECLIA in high-risk populations.

***Research perspectives***

Automated assays such as ECLIA using DBS increases diagnostic speed, generating the diagnosis of many samples at once, which can be important during potential outbreaks in hemotherapy clinics.

**ACKNOWLEDGEMENTS**

The authors would like to acknowledge technicians of the Viral Hepatitis Laboratory, especially, da Silva EF for technical assistance in the sample processing.

**REFERENCES**

1 **World Health Organization**. Hepatitis B [cited 2020 July 27]. Available from: http://www.who.int/news-room/fact-sheets/detail/hepatitis-b

2 **World Health Organization**. Hepatitis C [cited 2020 July 27]. Available from: http://www.who.int/news-room/fact-sheets/detail/hepatitis-c

3 **Villar LM,** Cruz HM, Portilho MM, Barbosa JR, Mendonça ACF, Flores GL. Emergence of New Epidemiological Hepatitis B and C Profiles in High Risk Groups in Latin America. In: Majumder MAA; Kabir R, Rahman S editors. Public Health Emerging and Re-Emerging Issues. New York: InTech Open; 2018 [DOI: 10.5772/intechopen.79174]

4 **Karkar A**, Abdelrahman M, Ghacha R, Malik TQ. Prevention of viral transmission in HD units: the value of isolation. *Saudi J Kidney Dis Transpl* 2006; **17**: 183-188 [PMID: 16903625]

5 **Bernieh B**. Viral hepatitis in hemodialysis: An update. *J Transl Int Med* 2015; **3**: 93-105 [PMID: 27847896 DOI: 10.1515/jtim-2015-0018]

6 **Brazil Health Ministry**. Profile of hereditary coagulopathies in Brazil: 2015. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/perfil\_coagulopatias\_hereditarias\_brasil\_2015.pdf

7 **Ribeiro Barbosa J**, Sousa Bezerra C, Carvalho-Costa FA, Pimentel de Azevedo C, Lopes Flores G, Baima Colares JK, Malta Lima D, Lampe E, Melo Villar L. Cross-Sectional Study to Determine the Prevalence of Hepatitis B and C Virus Infection in High Risk Groups in the Northeast Region of Brazil. *Int J Environ Res Public Health* 2017; **14** [PMID: 28714924 DOI: 10.3390/ijerph14070793]

8 **Ferreira AA**, Leite IC, Bustamante-Teixeira MT, Guerra MR. Hemophilia A in Brazil - epidemiology and treatment developments. *J Blood Med* 2014; **5**: 175-184 [PMID: 25288890 DOI: 10.2147/JBM.S68234]

9 **Ogishi M**, Yotsuyanagi H, Tsutsumi T, Gatanaga H, Ode H, Sugiura W, Moriya K, Oka S, Kimura S, Koike K. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. *PLoS One* 2015; **10**: e0119145 [PMID: 25748426 DOI: 10.1371/journal.pone.0119145]

10 **Flores GL**, de Almeida AJ, Miguel JC, Cruz HM, Portilho MM, Scalioni Lde P, Marques VA, Lewis-Ximenez LL, Lampe E, Villar LM. A Cross Section Study to Determine the Prevalence of Antibodies against HIV Infection among Hepatitis B and C Infected Individuals. *Int J Environ Res Public Health* 2016; **13** [PMID: 26978383 DOI: 10.3390/ijerph13030314]

11 **Flores GL**, Cruz HM, Marques VA, Villela-Nogueira CA, Potsch DV, May SB, Brandão-Mello CE, Pires MMA, Pilotto JH, Pollo-Flores P, Esberard EBC, Ivantes C, Lewis-Ximenez LL, Lampe E, Villar LM. Performance of ANTI-HCV testing in dried blood spots and saliva according to HIV status. *J Med Virol* 2017; **89**: 1435-1441 [PMID: 28165155 DOI: 10.1002/jmv.24777]

12 **Villar LM**, Bezerra CS, Cruz HM, Portilho MM, Flores GL. Applicability of Oral Fluid and Dried Blood Spot for Hepatitis B Virus Diagnosis. *Can J Gastroenterol Hepatol* 2019; **2019**: 5672795 [PMID: 31058110 DOI: 10.1155/2019/5672795]

13 **Flores GL**, Cruz HM, Potsch DV, May SB, Brandão-Mello CE, Pires MMA, Pilotto JH, Lewis-Ximenez LL, Lampe E, Villar LM. Evaluation of HBsAg and anti-HBc assays in saliva and dried blood spot samples according HIV status. *J Virol Methods* 2017; **247**: 32-37 [PMID: 28506632 DOI: 10.1016/j.jviromet.2017.05.004]

14 **Wang L**, Chen W, Yu Y. The Performance of the Abbott i2000 for Measuring Serum Markers of Infectious Diseases. *J Clin Lab Anal* 2017; **31** [PMID: 27302692 DOI: 10.1002/jcla.22015]

15 **Villar LM**, Cruz HM, Deodato RM, Miguel JC, da Silva EF, Flores GL, Lewis-Ximenez LL. Usefulness of automated assays for detecting hepatitis B and C markers in dried blood spot samples. *BMC Res Notes* 2019; **12**: 523 [PMID: 31429797 DOI: 10.1186/s13104-019-4547-y]

16 **Villar LM**, de Oliveira JC, Cruz HM, Yoshida CF, Lampe E, Lewis-Ximenez LL. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. *J Med Virol* 2011; **83**: 1522-1529 [PMID: 21739441 DOI: 10.1002/jmv.22138]

17 **Soulier A**, Poiteau L, Rosa I, Hézode C, Roudot-Thoraval F, Pawlotsky JM, Chevaliez S. Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment Monitoring. *J Infect Dis* 2016; **213**: 1087-1095 [PMID: 26333945 DOI: 10.1093/infdis/jiv423]

18 **Mössner BK**, Staugaard B, Jensen J, Lillevang ST, Christensen PB, Holm DK. Dried blood spots, valid screening for viral hepatitis and human immunodeficiency virus in real-life. *World J Gastroenterol* 2016; **22**: 7604-7612 [PMID: 27672281 DOI: 10.3748/wjg.v22.i33.7604]

19 **da Motta LR**, Adami AG, Sperhacke RD, Kato SK, Paganella MP, Pereira GFM, Benzaken AS. Hepatitis B and C prevalence and risk factors among young men presenting to the Brazilian Army: A STROBE-compliant national survey-based cross-sectional observational study. *Medicine (Baltimore)* 2019; **98**: e16401 [PMID: 31393348 DOI: 10.1097/MD.0000000000016401]

20 **Villar LM**, de Paula VS, de Almeida AJ, do Ó KM, Miguel JC, Lampe E. Knowledge and prevalence of viral hepatitis among beauticians. *J Med Virol* 2014; **86**: 1515-1521 [PMID: 24916521 DOI: 10.1002/jmv.23993]

21 **White SL**, Rawlinson W, Boan P, Sheppeard V, Wong G, Waller K, Opdam H, Kaldor J, Fink M, Verran D, Webster A, Wyburn K, Grayson L, Glanville A, Cross N, Irish A, Coates T, Griffin A, Snell G, Alexander SI, Campbell S, Chadban S, Macdonald P, Manley P, Mehakovic E, Ramachandran V, Mitchell A, Ison M. Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. *Transplant Direct* 2019; **5**: e416 [PMID: 30656214 DOI: 10.1097/TXD.0000000000000852]

22 **Brazilian Health Ministry**. Epidemiological Bulletin viral hepatitis 2019 [cited 2020 January 20]. Available from: http://www.aids.gov.br/pt-br/pub/2019/boletim-epidemiologico-de-hepatites-virais-2019

23 **Brandão NA**, Pfrimer IA, Martelli CM, Turchi MD. Prevalence of hepatitis B and C infection and associated factors in people living with HIV in Midwestern Brazil. *Braz J Infect Dis* 2015; **19**: 426-430 [PMID: 25766773 DOI: 10.1016/j.bjid.2015.02.001]

24 **Cardona-Arias JA**, Correa JCC, Higuita-Gutiérrez LF. Prevalence of hepatitis B/C viruses and associated factors in key groups attending a health services institution in Colombia, 2019. *PLoS One* 2020; **15**: e0238655 [PMID: 32960901 DOI: 10.1371/journal.pone.0238655]

25 **Candotti D**, Assennato SM, Laperche S, Allain JP, Levicnik-Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. *Gut* 2019; **68**: 313-321 [PMID: 29959168 DOI: 10.1136/gutjnl-2018-316490]

26 **Lelie N**, Vermeulen M, van Drimmelen H, Coleman C, Bruhn R, Reddy R, Busch M, Kleinman S. Direct comparison of three residual risk models for hepatitis B virus window period infections using updated input parameters. *Vox Sang* 2020; **115**: 133-145 [PMID: 31960480 DOI: 10.1111/vox.12889]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by FIOCRUZ Ethics Committee, CAAE No. 34055514.9.3010.5258 and No. 1.001.477.

**Informed consent statement:** All study participants provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** There are no conflicts of interest to report.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** August 17, 2020

**First decision:** October 21, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Rostami-Nejad M, Tabll AA **S-Editor:** Huang P **L-Editor:** Filipodia **P-Editor:**

**Table 1 Main sociodemographic and clinical characteristics of chronic kidney disease individuals, people living with human immunodeficiency virus and coagulopathy individuals**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **I\_CKD** | **P\_HIV** | **I\_COAG** |
| ***n* (%)** | ***n* (%)** | ***n* (%)** |
| Gender | Female | 101 (37.3) | 37 (38.9) | 1 (2.0) |
| Male | 170 (62.7) | 58 (61.1) | 50 (98.0) |
| Age | 18-30 | 19 (7.0) | 9 (9.5) | 25 (50.0) |
| 30+ | 253 (93.0) | 86 (90.5) | 25 (50.0) |
| Marital status | Married | 132 (49.3) | 31 (35.2) | 17 (33.3) |
| Not married | 136 (50.7) | 57 (64.8) | 34 (66.7) |
| Race | White | 71 (27.6) | 29 (46.0) | 14 (29.2) |
| Black | 186 (72.4) | 34 (54.0) | 34 (70.8) |
| Length of education | Up to 8 yr | 136 (51.1) | 36 (38.7) | 14 (27.5) |
| 9 or more | 130 (48.9) | 57 (61.3) | 37 (72.5) |
| Acupuncture | Yes | 21 (7.8) | 9 (9.5) | 15 (29.4) |
| No | 247 (92.2) | 86 (90.5) | 36 (70.6) |
| Tattoo | Yes | 27 (10.1) | 29 (31.2) | 6 (12.0) |
| No | 240 (89.9) | 64 (68.8) | 44 (88.0) |
| Piercing | Yes | 9 (3.4) | 7 (7.5) | 2 (4.1) |
| No | 259 (96.6) | 86 (92.5) | 47 (95.9) |
| Shared nail cutters/razor/toothbrush | Yes | 190 (66.9) | 70 (74.5) | 22 (43.1) |
| No | 94 (33.1) | 24 (25.5) | 29 (56.9) |
| Blood or plasma transfusion | Yes | 169 (63.3) | 16 (17.2) | 35 (70.0) |
| No | 98 (36.7) | 77 (82.8) | 15 (30.0) |
| Transfusion before 1994 | Yes | 34 (12.8) | 7 (7.5) | 25 (49.0) |
| No | 231 (87.2) | 86 (92.5) | 26 (51.0) |
| HBV vaccine | Yes | 206 (72.5) | 41 (43.2) | 36 (70.6) |
| No | 78 (27.5) | 54 (56.8) | 15 (29.4) |
| Use of illicit drugs | Yes | 18 (6.9) | 22 (23.9) | 6 (12.2) |
| No | 244 (93.1) | 70 (76.1) | 43 (87.8) |
| History of STI | Yes | 61 (23.0) | 44 (51.8) | 10 (20.0) |
| No | 204 (77.0) | 41 (48.2) | 40 (80.0) |
| Alcohol consumption | Yes | 48 (18.0) | 31 (41.3) | 30 (60.0) |
| No | 219 (82.0) | 44 (58.7) | 20 (40.0) |
| Condom use | Frequent | 66 (25.6) | 57 (64.0) | 18 (39.1) |
| Infrequent | 192 (74.4) | 32 (36.0) | 28 (60.9) |
| Hemodialysis per week | 3 times | 236 (89.4) | - | - |
| 4 times or more | 28 (10.6) | - | - |
| Hemodialysis time (mo) |  | 76.1 (80.1) | - | - |
| Coagulopathy | Hemophilia | - | - | 47 (92.2) |
| von Willebrand 3 | - | - | 4 (7.8) |
| Type of hemophilia | Deficiency factor VIII | - | - | 39 (84.8) |
| Factor IV deficiency | - | - | 7 (15.2) |
| Severity | Mild/moderate | - | - | 13 (28.3) |
| Serious | - | - | 33 (71.7) |
| Inhibitory antibodies | Present | - | - | 5 (11.4) |
| Absent | - | - | 39 (88.6) |

I\_CKD: Chronic kidney disease individuals; HBV: Hepatitis B virus; I\_COAG: Coagulopathy individuals; P\_HIV: People living with human immunodeficiency virus; STI: Sexually transmitted infection.

**Table 2 Bivariate analysis of sociodemographic and clinical characteristics according to hepatitis B virus and hepatitis C virus markers in chronic kidney disease individuals**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Adjustment** | **HBsAg** | **Anti-HBc** | **Anti-HCV** |
| **DBS** | **Serum** | **DBS** | **Serum** | **DBS** | **Serum** |
| Acupuncture | OR crude (95%CI) | - | - | - | 4.0 (1.5-10.6) | - | - |
| OR adjusted (95%CI) | - | - | - | 5.1 (1.8-14.5) | - | - |
| Shared nail cutters/razor /toothbrush | OR crude (95%CI) | - | - | 2.6 (1.4-4.6) | 1.9 (1.1-3.2) | - | - |
| OR adjusted (95%CI) | - | - | 2.7 (1.5-4.8) | 2.6 (1.5-4.7) | - | - |
| History of transplant | OR crude (95%CI) | - | - | 2.9 (1.3-6.4) | - | 5.8 (2.5-13.6) | 5.8 (2.5-13.6) |
| OR adjusted (95%CI) | - | - | 2.7 (1.2-6.1) | - | 2.8 (1.1-7.4) | 2.8 (1.1-7.7) |
| Infrequent condom use | OR crude (95%CI) | 5.6 (1.6-16.4) | 4.4 (1.4-14.5) | - | - | - | - |
| OR adjusted (95%CI) | 5.6 (1.6-16.4) | 4.4 (1.4-14.5) | - | - | - | - |
| Hemodialysis time (mo) | OR crude (95%CI) | - | - | - | 1.01 (1.01-1.01) | 1.01 (1.01-1.02) | 1.01 (1.01-1.01) |
| OR adjusted (95%CI) | - | - | - | 1.01 (1.01-1.01) | 1.01 (1.01-1.02) | 1.01 (1.01-1.02) |
| Hemodialysis 4 times per week or more | OR crude (95%CI) | - | - | - | - | - | 2.8 (1.1-6.9) |
| OR adjusted (95%CI) | - | - | - | - | - | 2.7 (1.1-7.4) |

CI: Confidence interval; DBS: Dried blood spot; HBc: Hepatitis B core; HCV: Hepatitis C virus; OR: Odds ratio.

**Table 3 Bivariate analysis of sociodemographic and clinical characteristics according to hepatitis B virus and hepatitis C virus markers in people living with human immunodeficiency virus**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Adjustment** | **HBsAg** | **Anti-HBc** | **Anti-HCV** |
| **DBS**  | **Serum** | **DBS**  | **Serum** | **DBS**  | **Serum** |
| Male gender | OR crude (95%CI) | - | 4.7 (1.3-17.4) | 3.2 (1.3-7.8) | 2.9 (1.1-7.3) | - | - |
| OR adjusted (95%CI) | - | 4.9 (1.2-19.2) | 3.2 (1.3-7.8) | 2.9 (1.1-7.3) | - | - |
| Blood or plasma transfusion | OR crude (95%CI) | - | 4.2 (1.3-13.5) | - | - | - | - |
| OR adjusted (95%CI) | - | 4.6 (1.3-16.0) | - | - | - | - |

CI: Confidence interval; DBS: Dried blood spot; HBc: Hepatitis B core; HCV: Hepatitis C virus; OR: Odds ratio.

**Table 4 Test parameter values according to individuals with coagulopathies, chronic kidney disease and people living with human immunodeficiency virus**

|  |  |  |  |
| --- | --- | --- | --- |
| **Diagnostic test parameters** | **I\_COAG, *n* = 51** | **I\_CKD, *n* = 284** | **P\_HIV, *n* = 95** |
| **HBsAg** | **Anti-HBc** | **Anti-HCV** | **HBsAg** | **Anti-HBc** | **Anti-HCV** | **HBsAg** | **Anti-HBc** | **Anti-HCV** |
| True positive (*n*) | 2 | 13 | 20 | 13 | 90 | 43 | 17 | 35 | 24 |
| True negative (*n*) | 49 | 35 | 26 | 270 | 165 | 235 | 71 | 48 | 70 |
| False positive (*n*) | 0 | 0 | 1 | 1 | 5 | 2 | 4 | 6 | 0 |
| False negative (*n*) | 0 | 3 | 4 | 0 | 23 | 3 | 3 | 1 | 0 |
| Sensitivity (%) | 100 | 81.3 | 83.3 | 100 | 79.6 | 93.5 | 85.0 | 97.2 | 100 |
| Specificity (%) | 100 | 100 | 96.3 | 99.6 | 97.1 | 99.2 | 94.7 | 88.9 | 100 |
| PPV (%) | 100 | 100 | 95.2 | 92.9 | 94.7 | 95.6 | 81.0 | 85.4 | 100 |
| NPV (%) | 100 | 92.1 | 86.7 | 100 | 87.8 | 98.7 | 95.9 | 98.0 | 100 |
| Correct classification (accuracy) (%) | 100 | 94.1 | 90.2 | 99.6 | 90.1 | 98.2 | 92.6 | 92.2 | 100 |
| Incorrect classification (%) | 0 | 5.9 | 9.8 | 0.4 | 9.9 | 1.8 | 7.4 | 7.8 | 0 |
| Estimated prevalence/serum (%) | 3.9 | 31.4 | 47.1 | 4.6 | 39.9 | 16.3 | 21.1 | 40.0 | 25.5 |
| Estimated prevalence/DBS (%) | 3.9 | 25.5 | 41.2 | 4.9 | 33.6 | 15.9 | 22.1 | 45.6 | 25.5 |

DBS: Dried blood spot; HBc: Hepatitis B core; HCV: Hepatitis C virus; I\_CKD: Chronic kidney disease individuals; I\_COAG: Coagulopathy individuals; NPV: Negative predictive value; P\_HIV: People living with human immunodeficiency virus; PPV: Positive predictive value.